Mini Review ARTICLE
Treating cocaine addiction, obesity, and emotional disorders by viral gene transfer of butyrylcholinesterase
- 1Pharmacology, Mayo Clinic Minnesota, United States
Butyrylcholinesterase (BChE), a plasma enzyme that hydrolyses the neurotransmitter, acetylcholine relatively well, with far lower efficiency than acetylcholinesterase (AChE) but with the capability to degrade a broad range of bioactive esters. AChE is universally understood as essential to cholinergic neurotransmission, voluntary muscle performance, and cognition, among other roles, and its catalytic impact is essential for life. A total absence of BChE activity, whether by enzyme inhibition or simple lack of enzyme protein is not only compatible with life, but does not lead to obvious physiologic disturbance. However, very recent studies at Mayo Clinic have amassed support for the concept that BChE does have a true physiological role as a “ghrelin hydrolase” and, pharmacologically, as a cocaine hydrolase. Human subjects and animal mutations that lack functional BChE show higher than normal levels of ghrelin, an acylated peptide that drives hunger and feeding, along with certain emotional behaviors. Mice treated by viral gene transfer of BChE show higher plasma levels of enzyme and lower levels of ghrelin. Ghrelin is acknowledged as a key driver of food-seeking and stress. This brief review examines some key phenomena and considers means of modulating BChE as treatments for cocaine addiction, anxiety, aggression, and obesity.
Keywords: Butyrylcholinesterase, Cocaine, Ghrelin, Addiction, Obesity, stress, viral gene transfer
Received: 20 Nov 2017;
Accepted: 31 Jan 2018.
Edited by:Patrick Masson, Kazan Federal University, Russia
Reviewed by:Alfonso Abizaid, Carleton University, Canada
Asta Tvarijonaviciute, Universidad de Murcia, Spain
Copyright: © 2018 Brimijoin, Gao, Geng and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Prof. Stephen Brimijoin, Mayo Clinic Minnesota, Pharmacology, 200 First StreetSW, Rochester, 55905, MN, United States, email@example.com